These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9253876)

  • 1. In vitro activity of cefoperazone-sulbactam: Singapore experience.
    Kumarasinghe G; Chow C; Chiu C; Cheong YM
    Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):734-7. PubMed ID: 9253876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of cefoperazone-sulbactam combination against cefoperazone resistant clinical isolates in a Malaysian general hospital.
    Lim VK; Cheong YM
    Malays J Pathol; 1995 Dec; 17(2):73-6. PubMed ID: 8935129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria.
    Wang FD; Lin ML; Lee WS; Liu CY
    Int J Antimicrob Agents; 2004 Jun; 23(6):590-5. PubMed ID: 15194130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli.
    Poudyal N; Gyawali N; Gurung R; Bhattarai NR; Baral R; Khanal B; Shrestha S; Amatya R; Bhattacharya SK
    Nepal Med Coll J; 2012 Mar; 14(1):5-8. PubMed ID: 23441486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of drug resistance among gram-negative bacilli isolated from admitted cases in a tertiary care centre.
    Chitnis SV; Chitnis V; Sharma N; Chitnis DS
    J Assoc Physicians India; 2003 Jan; 51():28-32. PubMed ID: 12693450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Activity of cefoperazone and cefoperazone-sulbactam against gram-positive and gram-negative bacteria].
    Baykal M; Hasçelik G
    Mikrobiyol Bul; 1990 Oct; 24(4):383-5. PubMed ID: 2287298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Distribution and drug-resistance of 3 500 gram-negative bacteria in Guangzhou].
    Xiao QZ; Su DH; Jiang JH; Zhong NS
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Feb; 25(2):132-8. PubMed ID: 15698988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp].
    Vay CA; Almuzara MN; Rodríguez CH; Pugliese ML; Lorenzo Barba F; Mattera JC; Famiglietti AM
    Rev Argent Microbiol; 2005; 37(1):34-45. PubMed ID: 15991478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ; Wang H;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 13. [In vitro antibacterial activity of sulperazone on multi-resistant strains of bacteria from burn wounds].
    Xu W; Chen X
    Zhonghua Wai Ke Za Zhi; 1995 Jul; 33(7):390-2. PubMed ID: 8565723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli.
    Harbarth S; Harris AD; Carmeli Y; Samore MH
    Clin Infect Dis; 2001 Nov; 33(9):1462-8. PubMed ID: 11588690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro antibacterial activity of cefoperazone-sulbactam].
    Zhang Y; Zhang J; Zhou L
    Zhonghua Nei Ke Za Zhi; 1995 Oct; 34(10):676-9. PubMed ID: 8731829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sensitivity of multiresistant bacterial strains to imipenem (Tienam)].
    Ruczkowska J; Dolna I
    Przegl Lek; 1992; 49(5):151-3. PubMed ID: 1438917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center.
    Rolston KV; Elting L; Waguespack S; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1996; 42(5):348-53. PubMed ID: 8874974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.